Biasing the prostaglandin F2α receptor responses toward EGFR-dependent transactivation of MAPK

Molecular Endocrinology

Volumn 26, Issue 7, 2012, Pages 1189-1202

  Goupil, Eugénie ^a,b   Wisehart, Veronica ^a   Khoury, Etienne ^a   Zimmerman, Brandon ^a,b   Jaffal, Sahar ^a,b   Hébert, Terence E ^b   Laporte, Stéphane A ^a,b  

^a RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

11 FLUORO 9,15 DIHYDROXY 15 (2 INDANYL) 16,17,18,19,20 PENTANORPROSTA 5,13 DIENOIC ACID; BETA ARRESTIN; BIMATOPROST; CLOPROSTENOL; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUPROSTENOL; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROSTAGLANDIN F2 ALPHA DERIVATIVE; PROSTAGLANDIN F2 ALPHA RECEPTOR; PROSTAGLANDIN RECEPTOR; THYMIDINE; UNCLASSIFIED DRUG;

ARTICLE; CELL NUCLEUS; CELL PROLIFERATION; CYTOSOL; DRUG RECEPTOR BINDING; ENZYME ACTIVATION; HUMAN; HUMAN CELL; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION;

ARRESTINS; CELL PROLIFERATION; DINOPROST; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HEK293 CELLS; HUMANS; INOSITOL; MAP KINASE SIGNALING SYSTEM; PROTEIN BINDING; PROTEIN KINASE C; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, PROSTAGLANDIN;

EID: 84863315292     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2011-1245     Document Type: Article

References (59)

1. Makino S, Zaragoza DB, Mitchell BF, Robertson S, Olson DM 2007 Prostaglandin F2α and its receptor as activators of human decidua. Semin Reprod Med 25:60-68
2. Olson DM, Zaragoza DB, Shallow MC, Cook JL, Mitchell BF, Grigsby P, Hirst J 2003 Myometrial activation and preterm labour: evidence supporting a role for the prostaglandin F receptor-a review. Placenta 24(Suppl A):S47-S54
3. Breyer MD, Breyer RM 2001 G protein-coupled prostanoid receptors and the kidney. Annu Rev Physiol 63:579-605
4. Lee PY, Shao H, Xu LA, Qu CK 1988 The effect of prostaglandin F2α on intraocular pressure in normotensive human subjects. Invest Ophthalmol Vis Sci 29:1474-1477
5. Lai J, Jin H, Yang R, Winer J, Li W, Yen R, King KL, Zeigler F, Ko A, Cheng J, Bunting S, Paoni NF 1996 Prostaglandin F2α induces cardiac myocyte hypertrophy in vitro and cardiac growth in vivo. Am J Physiol 271:H2197-H2208
6. Kamon M, Fujita D, Goto N, Amano H, Sakamoto K 2008 Prostaglandin F(2α) negatively regulates bone resorption in murine osteoclast development. Prostaglandins Other Lipid Mediat 87: 26-33
7. Hakeda Y, Harada S, Matsumoto T, Tezuka K, Higashino K, Kodama H, Hashimoto-Goto T, Ogata E, Kumegawa M 1991 Prostaglandin F2α stimulates proliferation of clonal osteoblastic MC3T3-E1 cells by up-regulation of insulin-like growth factor I receptors. J Biol Chem 266:21044-21050
8. Chen DB, Westfall SD, Fong HW, Roberson MS, Davis JS 1998 Prostaglandin F2α stimulates the Raf/MEK1/mitogen-activated protein kinase signaling cascade in bovine luteal cells. Endocrinology 139:3876-3885
9. Pierce KL, Fujino H, Srinivasan D, Regan JW 1999 Activation of FP prostanoid receptor isoforms leads to Rho-mediated changes in cell morphology and in the cell cytoskeleton. J Biol Chem 274:35944-35949
10. Goupil E, Tassy D, Bourguet C, Quiniou C, Wisehart V, Petrin D, Legouill C, Devost D, Zingg HH, Bouvier M, Saragovi HU, Chem-tob S, Lubell WD, Claing A, Hebert TE, Laporte SA 2010 A novel biased allosteric compound inhibitor of parturition, selectively impedes the PGF2α -mediated rho/rock signaling pathway. J Biol Chem 285:25624-25636
11. Davis JS, Weakland LL, Weiland DA, Farese RV, West LA 1987 Prostaglandin F2α stimulates phosphatidylinositol 4,5-bisphos-phate hydrolysis and mobilizes intracellular Ca2+ in bovine luteal cells. Proc Natl Acad Sci USA 84:3728-3732
12. Jimenez de Asua L, Goin M 1997 Prostaglandin F2α (PGF2α) triggers protein kinase C (PKC) and tyrosine kinase activity in cultured mammalian cells. Adv Exp Med Biol 400A:531-538
13. Ito S, Sakamoto K, Mochizuki-Oda N, Ezashi T, Miwa K, Okuda-Ashitaka E, Shevchenko VI, Kiso Y, Hayaishi O 1994 Prostaglandin F2α receptor is coupled to Gq in cDNA-transfected Chinese hamster ovary cells. Biochem Biophys Res Commun 200:756-762
14. Daaka Y, Luttrell LM, Ahn S, Della Rocca GJ, Ferguson SS, Caron MG, Lefkowitz RJ 1998 Essential role for G protein-coupled receptor endocytosis in the activation of mitogen-activated protein kinase. J Biol Chem 273:685-688
15. Dikic I, Tokiwa G, Lev S, Courtneidge SA, Schlessinger J 1996 A role for Pyk2 and Src in linking G-protein-coupled receptors with MAP kinase activation. Nature 383:547-550
16. Daaka Y, Luttrell LM, Lefkowitz RJ 1997 Switching of the coupling of the β2-adrenergic receptor to different G proteins by protein kinase A. Nature 390:88-91
17. Pierce KL, Luttrell LM, Lefkowitz RJ 2001 New mechanisms in heptahelical receptor signaling to mitogen activated protein kinase cascades. Oncogene 20:1532-1539
18. Kenakin T 2003 Ligand-selective receptor conformations revisited: the promise and the problem. Trends Pharmacol Sci 24:346-354
19. Galandrin S, Oligny-Longpre G, Bouvier M 2007 The evasive nature of drug efficacy: implications for drug discovery. Trends Pharmacol Sci 28:423-430
20. Wang L, Martin B, Brenneman R, Luttrell LM, Maudsley S 2009 Allosteric modulators of g protein-coupled receptors: future therapeutics for complex physiological disorders. J Pharmacol Exp Ther 331:340-348
21. Digby GJ, Conn PJ, Lindsley CW 2010 Orthosteric- and allosteric-induced ligand-directed trafficking at GPCRs. Curr Opin Drug Dis-cov Dev 13:587-594
22. Conn PJ, Christopoulos A, Lindsley CW 2009 Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat Rev Drug Discov 8:41-54
23. Griffin BW, Klimko P, Crider JY, Sharif NA 1999 AL-8810: a novel prostaglandin F2α analog with selective antagonist effects at the prostaglandin F2α (FP) receptor. J Pharmacol Exp Ther 290:1278 -1284
24. Ueno T, Fujimori K 2011 Novel suppression mechanism operating in early phase of adipogenesis by positive feedback loop for enhancement of cyclooxygenase-2 expression through prostaglandin F2α receptor mediated activation of MEK/ERK-CREB cascade. FEBS J 278:2901-2912
25. Husain S, Jafri F, Crosson CE 2005 Acute effects of PGF2α on MMP-2 secretion from human ciliary muscle cells: a PKC- and ERK-dependent process. Invest Ophthalmol Vis Sci 46:1706-1713
26. Sales KJ, Boddy SC, Williams AR, Anderson RA, Jabbour HN 2007 F-prostanoid receptor regulation of fibroblast growth factor 2 signaling in endometrial adenocarcinoma cells. Endocrinology 148: 3635-3644
27. Woodward DF, Krauss AH, Wang JW, Protzman CE, Nieves AL, Liang Y, Donde Y, Burk RM, Landsverk K, Struble C 2007 Identification of an antagonist that selectively blocks the activity of prostamides (prostaglandin-ethanolamides) in the feline iris. Br J Pharmacol 150:342-352
28. Zimmerman B, Simaan M, Lee MH, Luttrell LM, Laporte SA 2009 c-Src-mediated phosphorylation of AP-2 reveals a general mechanism for receptors internalizing through the clathrin pathway. Cell Signal 21:103-110
29. Fessart D, Simaan M, Zimmerman B, Comeau J, Hamdan FF, Wiseman PW, Bouvier M, Laporte SA 2007 Src-dependent phosphorylation of β2-adaptin dissociates the β -arrestin-AP-2 complex. J Cell Sci 120:1723-1732
30. Harvey CD, Ehrhardt AG, Cellurale C, Zhong H, Yasuda R, Davis RJ, Svoboda K 2008 A genetically encoded fluorescent sensor of ERK activity. Proc Natl Acad Sci USA 105:19264-19269
31. Samadfam R, Gallant MA, Miousse MC, Parent JL, de Brum-Fernandes AJ 2006 Implication of prostaglandin receptors in the accumulation of osteoprotegerin in human osteoblast cultures. J Rheumatol 33:1167-1175
32. Ahmed I, Gesty-Palmer D, Drezner MK, Luttrell LM 2003 Trans-activation of the epidermal growth factor receptor mediates parathyroid hormone and prostaglandin F2α -stimulated mitogen-acti-vated protein kinase activation in cultured transgenic murine osteoblasts. Mol Endocrinol 17:1607-1621
33. Prenzel N, Zwick E, Daub H, Leserer M, Abraham R, Wallasch C, Ullrich A 1999 EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 402:884-888
34. Lombardo CR, Consler TG, Kassel DB 1995 In vitro phosphorylation of the epidermal growth factor receptor autophosphoryla-tion domain by c-src: identification of phosphorylation sites and c-src SH2 domain binding sites. Biochemistry 34:16456-16466
35. Luttrell LM, Della Rocca GJ, van Biesen T, Luttrell DK, Lefkowitz RJ 1997 Gβγ subunits mediate Src-dependent phosphorylation of the epidermal growth factor receptor. A scaffold for G protein-coupled receptor-mediated Ras activation. J Biol Chem 272:4637-4644
36. Pouyssegur J, Volmat V, Lenormand P 2002 Fidelity and spatio-temporal control in MAP kinase (ERKs) signalling. Biochem Pharmacol 64:755-763
37. Ramos JW 2008 The regulation of extracellular signal-regulated kinase (ERK) in mammalian cells. Int J Biochem Cell Biol 40:2707-2719
38. Zhang W, Liu HT 2002 MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res 12:9-18
39. Meloche S, Pouyssegur J 2007 The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1 to S-phase transition. Oncogene 26:3227-3239
40. DeWire SM, Ahn S, Lefkowitz RJ, Shenoy SK 2007 β-arrestins and cell signaling. Annu Rev Physiol 69:483-510
41. Luttrell LM, Gesty-Palmer D 2010 Beyond desensitization: physiological relevance of arrestin-dependent signaling. Pharmacol Rev 62:305-330
42. Wei H, Ahn S, Shenoy SK, Karnik SS, Hunyady L, Luttrell LM, Lefkowitz RJ 2003 Independent β-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2. Proc Natl Acad Sci USA 100:10782-10787
43. Kim IM, Tilley DG, Chen J, Salazar NC, Whalen EJ, Violin JD, Rockman HA 2008 β-Blockers alprenolol and carvedilol stimulate β-arrestin-mediated EGFR transactivation. Proc Natl Acad Sci USA 105:14555-14560
44. Galandrin S, Oligny-Longpre G, Bonin H, Ogawa K, Gales C, Bouvier M 2008 Conformational rearrangements and signaling cascades involved in ligand-biased mitogen-activated protein kinase signaling through the β1-adrenergic receptor. Mol Pharmacol 74:162-172
45. Wisler JW, DeWire SM, Whalen EJ, Violin JD, Drake MT, Ahn S, Shenoy SK, Lefkowitz RJ 2007 A unique mechanism of β-blocker action: carvedilol stimulates β-arrestin signaling. Proc Natl Acad Sci USA 104:16657-16662
46. Reversi A, Rimoldi V, Marrocco T, Cassoni P, Bussolati G, Parenti M, Chini B 2005 The oxytocin receptor antagonist atosiban inhibits cell growth via a "biased agonist" mechanism. J Biol Chem 280:16311-16318
47. Powell WS, Hammarstrom S, Samuelsson B, Sjoberg B 1974 Letter: prostaglandin-F2α receptor in human corpora lutea. Lancet 1:1120
48. Schaaf TK, Hess HJ 1979 Synthesis and biological activity of car-boxyl-terminus modified prostaglandin analogues. J Med Chem 22:1340-1346
49. Maddox YT, Ramwell PW, Shiner CS, Corey EJ 1978 Amide and i-amino derivatives of F prostaglandins as prostaglandin antagonists. Nature 273:549-552
50. Schuster VL, Itoh S, Andrews SW, Burk RM, Chen J, Kedzie KM, Gil DW, Woodward DF 2000 Synthetic modification of prostaglandin F2α indicates different structural determinants for binding to the prostaglandin F receptor versus the prostaglandin transporter. Mol Pharmacol 58:1511-1516
51. Woodward DF, Krauss AH, Chen J, Gil DW, Kedzie KM, Protzman CE, Shi L, Chen R, Krauss HA, Bogardus A, Dinh HT, Wheeler LA, Andrews SW, Burk RM, Gac T, Roof MB, Garst ME, Kaplan LJ, Sachs G, Pierce KL, Regan JW, Ross RA, Chan MF 2000 Replacement of the carboxylic acid group of prostaglandin F2α with a hydroxyl or methoxy substituent provides biologically unique compounds. Br J Pharmacol 130:1933-1943
52. Kobilka BK, Deupi X 2007 Conformational complexity of G-protein-coupled receptors. Trends Pharmacol Sci 28:397-406
53. Deupi X, Kobilka BK 2010 Energy landscapes as a tool to integrate GPCR structure, dynamics, and function. Physiology (Bethesda) 25:293-303
54. Yoon S, Seger R 2006 The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors 24:21-44
55. Marshall CJ 1995 Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 80:179-185
56. Nguyen TT, Scimeca JC, Filloux C, Peraldi P, Carpentier JL, Van Obberghen E 1993 Co-regulation of the mitogen-activated protein kinase, extracellular signal-regulated kinase 1, and the 90-kDa ri-bosomal S6 kinase in PC12 cells. Distinct effects of the neurotrophic factor, nerve growth factor, and the mitogenic factor, epidermal growth factor. J Biol Chem 268:9803-9810
57. Traverse S, Gomez N, Paterson H, Marshall C, Cohen P 1992 Sustained activation of the mitogen-activated protein (MAP) kinase cascade may be required for differentiation of PC12 cells. Comparison of the effects of nerve growth factor and epidermal growth factor. Biochem J 288(Pt 2):351-355
58. New DC, Wong YH 2007 Molecular mechanisms mediating the G protein-coupled receptor regulation of cell cycle progression. J Mol Signal 2:2
59. Fujita T, Meguro T, Fukuyama R, Nakamuta H, Koida M 2002 New signaling pathway for parathyroid hormone and cyclic AMP action on extracellular-regulated kinase and cell proliferation in bone cells. Checkpoint of modulation by cyclic AMP. J Biol Chem 277:22191-22200